Physician profile
Kim Jackson
NPI 1902292329
$6,450.84
in general payments reported to CMS, 2019-2025
29 companies · $1,976 in 2025
The $1,976 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $104 · 2021: $469 · 2022: $1,029 · 2023: $1,194 · 2024: $1,355 · 2025: $1,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,390 · Education: $79.83 · Consulting Fee: $54.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,390.29 |
| Education | $79.83 |
| Consulting Fee | $54.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,080.21 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $899.25 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $647.79 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $575.13 | 2021-2025 | Dupixent |
| Genentech USA, INC. | $449.53 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $427.76 | 2021-2025 | |
| Csl Behring | $358.86 | 2019-2025 | Hizentra, Haegarda |
| Pharming Healthcare, INC. | $326.44 | 2019-2025 | Ruconest |
| Amgen INC. | $260.51 | 2022-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $183.13 | 2021-2025 | Orladeyo |
| Leo Pharma INC. | $177.33 | 2022-2025 | Adbry, Anzupgo |
| Grifols USA, LLC | $148.32 | 2022-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $128.90 | 2020-2025 | Cuvitru, Eohilia |
| Sanofi-Aventis U.S. LLC | $110.58 | 2019 | |
| Pfizer INC. | $110.17 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $104.42 | 2021-2023 | Auvi-Q |
| Hikma Pharmaceuticals USA | $92.17 | 2023-2024 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $69.45 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $54.42 | 2025 | |
| Mylan Specialty L.P. | $48.46 | 2024 | Yupelri |
| Paratek Pharmaceuticals, INC. | $39.36 | 2025 | Xhance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.16 | 2021 | |
| Greer Laboratories, INC. | $24.35 | 2025 | Oralair |
| Verona Pharma, INC. | $21.58 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $20.15 | 2025 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $16.76 | 2025 | Dawnzera |
| Merck Sharp & Dohme LLC | $15.76 | 2023 | |
| Optinose US, INC. | $15.34 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.